| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 05/03/2025 | 13:00 | GlobeNewswire Inc. | atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression | NASDAQ:ATAI | ATAI Life Sciences NV |
| 25/02/2025 | 03:59 | Edgar (US Regulatory) | Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership | NASDAQ:ATAI | ATAI Life Sciences NV |
| 24/02/2025 | 22:10 | GlobeNewswire Inc. | atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference | NASDAQ:ATAI | ATAI Life Sciences NV |
| 20/02/2025 | 13:00 | GlobeNewswire Inc. | atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares | NASDAQ:ATAI | ATAI Life Sciences NV |
| 20/02/2025 | 00:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ATAI | ATAI Life Sciences NV |
| 13/02/2025 | 22:37 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ATAI | ATAI Life Sciences NV |
| 13/02/2025 | 22:35 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:ATAI | ATAI Life Sciences NV |
| 13/02/2025 | 04:47 | GlobeNewswire Inc. | atai Life Sciences Announces Pricing of Public Offering of Common Shares | NASDAQ:ATAI | ATAI Life Sciences NV |
| 12/02/2025 | 22:01 | GlobeNewswire Inc. | atai Life Sciences Announces Proposed Public Offering of Common Shares | NASDAQ:ATAI | ATAI Life Sciences NV |
| 28/01/2025 | 13:00 | GlobeNewswire Inc. | atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder | NASDAQ:ATAI | ATAI Life Sciences NV |
| 10/01/2025 | 22:15 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ATAI | ATAI Life Sciences NV |
| 10/01/2025 | 13:00 | GlobeNewswire Inc. | atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health | NASDAQ:ATAI | ATAI Life Sciences NV |
| 13/11/2024 | 14:00 | GlobeNewswire Inc. | atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | NASDAQ:ATAI | ATAI Life Sciences NV |
| 11/11/2024 | 13:30 | GlobeNewswire Inc. | Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer | NASDAQ:ATAI | ATAI Life Sciences NV |
| 15/10/2024 | 14:00 | GlobeNewswire Inc. | atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit | NASDAQ:ATAI | ATAI Life Sciences NV |
| 04/09/2024 | 13:00 | GlobeNewswire Inc. | atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference | NASDAQ:ATAI | ATAI Life Sciences NV |
| 13/08/2024 | 13:10 | GlobeNewswire Inc. | atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates | NASDAQ:ATAI | ATAI Life Sciences NV |
| 13/08/2024 | 13:00 | GlobeNewswire Inc. | atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT) | NASDAQ:ATAI | ATAI Life Sciences NV |
| 07/08/2024 | 13:00 | GlobeNewswire Inc. | atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference | NASDAQ:ATAI | ATAI Life Sciences NV |
| 26/06/2024 | 13:00 | GlobeNewswire Inc. | atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference | NASDAQ:ATAI | ATAI Life Sciences NV |
| 20/06/2024 | 13:00 | GlobeNewswire Inc. | atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a | NASDAQ:ATAI | ATAI Life Sciences NV |
| 31/05/2024 | 13:00 | GlobeNewswire Inc. | atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference | NASDAQ:ATAI | ATAI Life Sciences NV |
| 23/05/2024 | 13:00 | GlobeNewswire Inc. | atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors | NASDAQ:ATAI | ATAI Life Sciences NV |
| 15/05/2024 | 13:53 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ATAI | ATAI Life Sciences NV |
| 15/05/2024 | 12:59 | GlobeNewswire Inc. | atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates | NASDAQ:ATAI | ATAI Life Sciences NV |
| 24/04/2024 | 13:00 | GlobeNewswire Inc. | atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression | NASDAQ:ATAI | ATAI Life Sciences NV |
| 17/04/2024 | 13:00 | GlobeNewswire Inc. | atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology | NASDAQ:ATAI | ATAI Life Sciences NV |
| 28/03/2024 | 12:00 | GlobeNewswire Inc. | atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights | NASDAQ:ATAI | ATAI Life Sciences NV |
| 27/03/2024 | 12:00 | GlobeNewswire Inc. | atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression | NASDAQ:ATAI | ATAI Life Sciences NV |
| 04/03/2024 | 14:00 | GlobeNewswire Inc. | atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01 | NASDAQ:ATAI | ATAI Life Sciences NV |
